MASS
Price
$11.51
Change
+$0.08 (+0.70%)
Updated
Oct 20 closing price
Capitalization
475.75M
19 days until earnings call
Intraday BUY SELL Signals
PACB
Price
$1.96
Change
+$0.12 (+6.52%)
Updated
Oct 20 closing price
Capitalization
609.23M
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MASS vs PACB

MASS vs PACB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MASS vs. PACB commentary
Oct 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MASS is a Hold and PACB is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MASS with price predictions
Oct 20, 2026

MASS's RSI Indicator leaves overbought zone

The 10-day RSI Indicator for MASS moved out of overbought territory on October 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 instances where the indicator moved out of the overbought zone. In 23 of the 25 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MASS as a result. In 80 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for MASS turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 43 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MASS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +2.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where MASS advanced for three days, in 221 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 106 of 132 cases where MASS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.753) is normal, around the industry mean (2.979). P/E Ratio (-12.116) is within average values for comparable stocks, (2.590). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (5.988) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MASS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MASS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
a Summary for PACB with price predictions
Oct 20, 2026

PACB in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 05, 2026

PACB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 49 similar instances where the stock broke above the upper band. In 45 of the 49 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PACB moved out of overbought territory on October 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 26 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PACB as a result. In 76 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for PACB turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 43 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

PACB moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PACB crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

The 50-day moving average for PACB moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +13.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in 221 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. In 119 of 138 cases where PACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PACB's P/B Ratio (-18.343) is slightly lower than the industry average of (2.979). P/E Ratio (-4.667) is within average values for comparable stocks, (2.590). PACB's Projected Growth (PEG Ratio) (180.110) is very high in comparison to the industry average of (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.565) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

FUNDAMENTALS RATINGS
MASS vs PACB: Fundamental Ratings
MASS
PACB
OUTLOOK RATING
1..100
9091
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
98
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
3536
P/E GROWTH RATING
1..100
9385
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MASS's Valuation (20) in the null industry is significantly better than the same rating for PACB (98) in the Biotechnology industry. This means that MASS’s stock grew significantly faster than PACB’s over the last 12 months.

MASS's Profit vs Risk Rating (100) in the null industry is in the same range as PACB (100) in the Biotechnology industry. This means that MASS’s stock grew similarly to PACB’s over the last 12 months.

MASS's SMR Rating (96) in the null industry is in the same range as PACB (100) in the Biotechnology industry. This means that MASS’s stock grew similarly to PACB’s over the last 12 months.

MASS's Price Growth Rating (35) in the null industry is in the same range as PACB (36) in the Biotechnology industry. This means that MASS’s stock grew similarly to PACB’s over the last 12 months.

PACB's P/E Growth Rating (85) in the Biotechnology industry is in the same range as MASS (93) in the null industry. This means that PACB’s stock grew similarly to MASS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MASSPACB
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
Bearish Trend 13 days ago
85%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
86%
COMPARISON
Comparison
Oct 21, 2026
Stock price -- (MASS: $11.51 vs. PACB: $1.96)
Brand notoriety: MASS and PACB are both not notable
Both companies represent the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: MASS: 87% vs. PACB: 86%
Market capitalization -- MASS: $475.75M vs. PACB: $609.23M
MASS [@Medical/Nursing Services] is valued at $475.75M. PACB’s [@Medical/Nursing Services] market capitalization is $609.23M. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $177.28B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MASS’s FA Score shows that 1 FA rating(s) are green while PACB’s FA Score has 0 green FA rating(s).

  • MASS’s FA Score: 1 green, 4 red.
  • PACB’s FA Score: 0 green, 5 red.
According to our system of comparison, MASS is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MASS’s TA Score shows that 3 TA indicator(s) are bullish while PACB’s TA Score has 6 bullish TA indicator(s).

  • MASS’s TA Score: 3 bullish, 4 bearish.
  • PACB’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, PACB is a better buy in the short-term than MASS.

Price Growth

MASS (@Medical/Nursing Services) experienced а -4.80% price change this week, while PACB (@Medical/Nursing Services) price change was -4.39% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.88%. For the same industry, the average monthly price growth was -9.59%, and the average quarterly price growth was -10.00%.

Reported Earning Dates

MASS is expected to report earnings on Nov 09, 2026.

PACB is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Medical/Nursing Services (-2.88% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
MASS
Daily Signal:
Gain/Loss:
PACB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INDP2.960.23
+8.42%
Indaptus Therapeutics Inc
INOD55.041.04
+1.94%
Innodata
APTV45.060.58
+1.30%
Aptiv PLC
UYSC11.00N/A
N/A
Uy Scuti Acquisition Corp
NTRSO18.30-0.01
-0.05%
Northern Trust Corp

MASS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MASS has been loosely correlated with PACB. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if MASS jumps, then PACB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MASS
1D Price
Change %
MASS100%
+0.70%
PACB - MASS
46%
Loosely correlated
+6.52%
TXG - MASS
39%
Loosely correlated
+2.25%
QSI - MASS
39%
Loosely correlated
+6.42%
BRKR - MASS
37%
Loosely correlated
+1.01%
TWST - MASS
35%
Loosely correlated
+2.10%
More

PACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with TXG. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then TXG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
+6.52%
TXG - PACB
52%
Loosely correlated
+2.25%
BFLY - PACB
52%
Loosely correlated
-2.14%
QSI - PACB
49%
Loosely correlated
+6.42%
ILMN - PACB
48%
Loosely correlated
+2.01%
MASS - PACB
46%
Loosely correlated
+0.70%
More